0001209191-21-008124.txt : 20210205
0001209191-21-008124.hdr.sgml : 20210205
20210205164958
ACCESSION NUMBER: 0001209191-21-008124
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210203
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Rosenberg Noah L.
CENTRAL INDEX KEY: 0001579649
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36257
FILM NUMBER: 21596740
MAIL ADDRESS:
STREET 1: C/O ESPERION THERAPEUTICS, INC.
STREET 2: 46701 COMMERCE CENTER DRIVE
CITY: PLYMOUTH
STATE: MI
ZIP: 48170
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Travere Therapeutics, Inc.
CENTRAL INDEX KEY: 0001438533
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262383102
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 888-969-7879
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DR
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
FORMER COMPANY:
FORMER CONFORMED NAME: Retrophin, Inc.
DATE OF NAME CHANGE: 20130220
FORMER COMPANY:
FORMER CONFORMED NAME: Desert Gateway, Inc.
DATE OF NAME CHANGE: 20080625
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-03
0
0001438533
Travere Therapeutics, Inc.
TVTX
0001579649
Rosenberg Noah L.
C/O RETROPHIN, INC.
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
0
1
0
0
Chief Medical Officer
Common Stock
2021-02-03
4
A
0
4500
0.00
A
48594
D
(1) On January 31, 2020, the reporting person was granted a performance restricted stock unit (PRSU) grant covering 9,000 shares of the Issuer's common stock, which vest upon the later of (i) 12 months from the date of grant and (ii) the achievement of specified clinical and regulatory development milestones. On February 3, 2021, a portion of the PRSUs vested upon the Issuer's confirmation of the satisfaction of a performance criterion related to the interim data read-out from the DUPLEX study.
/s/ Elizabeth E. Reed, Attorney-in-Fact
2021-02-05